BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15799406)

  • 21. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
    Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
    Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment.
    Lindsay K; Melsom R; Jacob BK; Mestry N
    Rheumatology (Oxford); 2006 Aug; 45(8):1048-9. PubMed ID: 16760195
    [No Abstract]   [Full Text] [Related]  

  • 23. [Anakinra for therapy of rheumatoid arthritis].
    Tomoo T; Sumida T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():534-7. PubMed ID: 15799413
    [No Abstract]   [Full Text] [Related]  

  • 24. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
    D'Alessandro G; Bianco MR; Politis S; Ferrandina C; Rossi G; Altomare E
    Reumatismo; 2006; 58(1):59-61. PubMed ID: 16639489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(5):201-3. PubMed ID: 12557112
    [No Abstract]   [Full Text] [Related]  

  • 26. Folic acid and folinic acid supplementation during low-dose methotrexate therapy for rheumatoid arthritis: comment on the article by van Ede et al.
    Morgan SL; Baggott JE; Alarcón GS; Koopman WJ
    Arthritis Rheum; 2002 May; 46(5):1413-4. PubMed ID: 12115259
    [No Abstract]   [Full Text] [Related]  

  • 27. Interstitial pneumonitis associated with infliximab therapy.
    Villeneuve E; St-Pierre A; Haraoui B
    J Rheumatol; 2006 Jun; 33(6):1189-93. PubMed ID: 16622902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.
    Roos JC; Chilvers ER; Ostor AJ
    J Rheumatol; 2007 Jan; 34(1):238-9; author reply 239. PubMed ID: 17216703
    [No Abstract]   [Full Text] [Related]  

  • 29. COMET results are not stellar.
    James M; Cleland L
    Lancet; 2008 Nov; 372(9652):1807-8; author reply 1808. PubMed ID: 19027480
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Martin Mola E; Pedersen R; Robertson D; Chang D; Koenig A; Freundlich B;
    Ann Rheum Dis; 2009 Jul; 68(7):1113-8. PubMed ID: 18718986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
    Sany J; Kaiser MJ
    Ann Med Interne (Paris); 2002 Feb; 153(1):34-40. PubMed ID: 11994688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
    Behrens F; Koehm M; Burkhardt H
    Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment continuation in patients receiving biological agents or conventional DMARD therapy.
    Zink A; Listing J; Kary S; Ramlau P; Stoyanova-Scholz M; Babinsky K; von Hinueber U; Gromnica-Ihle E; Wassenberg S; Antoni C; Herzer P; Kekow J; Schneider M; Rau R
    Ann Rheum Dis; 2005 Sep; 64(9):1274-9. PubMed ID: 15708884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of chronic polyarthritis with methotrexate 1994--a review].
    Rau R
    Z Rheumatol; 1994; 53(4):199-229. PubMed ID: 7975933
    [No Abstract]   [Full Text] [Related]  

  • 36. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
    Conaghan PG; Quinn MA; O'Connor P; Wakefield RJ; Karim Z; Emery P
    Arthritis Rheum; 2002 Jul; 46(7):1971-2; author reply 1973. PubMed ID: 12124886
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC; Cohen S; Moreland L; Lium D; Robbins S; Newmark R; Bekker P;
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor necrosis factor therapies.
    Taylor PC
    Curr Opin Rheumatol; 2001 May; 13(3):164-9. PubMed ID: 11333343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Infliximab in the treatment of rheumatoid arthritis].
    Akahoshi T; Watabe H
    Nihon Rinsho; 2002 Dec; 60(12):2378-83. PubMed ID: 12510365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Maintenance therapy for rheumatoid arthritis after remission following successful treatment using biologics].
    Ichikawa N; Yamanaka H
    Nihon Rinsho; 2007 Jul; 65(7):1293-8. PubMed ID: 17642246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.